GlassScriptPhysician profile
Michael B Russell
NPI 1730592387
$11,076.48
in general payments reported to CMS, 2019-2025
33 companies · $2,790 in 2025
The $2,790 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $196 · 2021: $710 · 2022: $2,142 · 2023: $2,418 · 2024: $2,591 · 2025: $2,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,767 · Education: $31.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,767.12 |
| Education | $31.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,245.86 | 2019-2025 | Linzess, Viberzi, Skyrizi |
| Janssen Biotech, INC. | $1,548.88 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,098.82 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,030.04 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $993.79 | 2021-2025 | |
| Pfizer INC. | $518.76 | 2021-2025 | |
| Genzyme Corporation | $410.40 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $314.68 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $281.07 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $226.89 | 2021-2024 | Linzess |
| Alnylam Pharmaceuticals INC. | $212.95 | 2021-2025 | Givlaari |
| Phathom Pharmaceuticals, INC. | $199.13 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $187.80 | 2021-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $173.44 | 2022-2024 | Rebyota, Cimzia |
| Amgen INC. | $164.74 | 2022-2023 | Avsola, Amjevita |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $159.62 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $159.12 | 2021-2023 | |
| Redhill Biopharma INC. | $149.14 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Lilly USA, LLC | $147.62 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $135.46 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $134.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $124.56 | 2021-2023 | Dificid |
| Intercept Pharmaceuticals, INC. | $120.56 | 2022-2024 | Ocaliva |
| Fresenius Kabi USA, LLC | $56.70 | 2023-2024 | Idacio |
| Novo Nordisk INC | $49.41 | 2024-2025 | Wegovy |
| Evoke Pharma, INC. | $45.63 | 2022 | |
| Celltrion USA INC. | $40.28 | 2024-2025 | Zymfentra, Vegzelma |
| Organon LLC | $31.41 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $30.30 | 2025 | Iqirvo |
| Blueprint Medicines Corporation | $27.26 | 2023 | |
| Vivus LLC | $26.95 | 2021-2024 | Pancreaze |
| Shire North American Group INC | $16.97 | 2019 | |
| Braintree Laboratories, INC. | $13.36 | 2023 | Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.